![]() |
|
|
Vol. 297, Issue 2, 736-745, May 2001
Center for Clinical Pharmacology, Departments of Pharmacology and
Medicine, University of Pittsburgh Medical Center, Pittsburgh,
Pennsylvania
To examine the actions of angiotensin II on regional vascular
resistances, we monitored regional blood flows and cardiac output with
transit-time flow probes and thermodilution, respectively, in
anesthetized rats. To remove the influence of endogenous angiotensin II, rats were pretreated with captopril (30 mg/kg intravenously). Intravenous infusions of angiotensin II were used to produce
circulating angiotensin II, and these infusions caused marked
dose-related (3, 30, and 300 pmol/min) and sustained (2 h) increases in
renal vascular resistance, with lesser effects on mesenteric vascular resistance, little effect on carotid vascular resistance, and no effect
on hindquarter or calculated "other tissue" vascular resistances.
In contrast, vasopressin caused similar increases in renal, mesenteric,
carotid, hindquarter, and other tissue vascular resistances. Infusions
of angiotensin II (3, 10, and 30 pmol/min) into the local arterial
blood were used to increase selectively local angiotensin II levels.
Intrarenal artery infusions of angiotensin II increased renal, but not
mesenteric, vascular resistance; and intramesenteric artery infusions
of angiotensin II increased mesenteric, but not renal, vascular
resistance. Infusions of angiotensin II into the hindquarter and
carotid vascular beds caused little change in hindquarter and carotid
vascular resistances, respectively, but sufficient angiotensin II
escaped the hindquarter and carotid vascular beds to cause increases in
renal and mesenteric vascular resistances. In conclusion, angiotensin
II constricts primarily the renal vascular bed and to a lesser extent
the gut circulation, and those tissues that are most responsive to
angiotensin II also metabolize angiotensin II better than tissues that
are less responsive to angiotensin II.
This article has been cited by other articles:
![]() |
C. S. Escano Jr., L. B. Keever, A. A. Gutweiler, and B. T. Andresen Angiotensin II Activates Extracellular Signal-Regulated Kinase Independently of Receptor Tyrosine Kinases in Renal Smooth Muscle Cells: Implications for Blood Pressure Regulation J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 34 - 42. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Hsu, P. T. Chao, H. Hsiu, W. K. Wang, S. P. Li, and Y. Y. L. Wang Organ-specific ligation-induced changes in harmonic components of the pulse spectrum and regional vasoconstrictor selectivity in Wistar rats Exp Physiol, January 1, 2006; 91(1): 163 - 170. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. T. Andresen, K. Shome, E. K. Jackson, and G. G. Romero AT2 receptors cross talk with AT1 receptors through a nitric oxide- and RhoA-dependent mechanism resulting in decreased phospholipase D activity Am J Physiol Renal Physiol, April 1, 2005; 288(4): F763 - F770. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Patten, M. J. Adams, J. A. Dallimore, and M. Y. Abeywardena Depressed Prostanoid-Induced Contractility of the Gut in Spontaneously Hypertensive Rats (SHR) Is Not Affected by the Level of Dietary Fat J. Nutr., November 1, 2004; 134(11): 2924 - 2929. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. K. Jackson and W. A. Herzer Renal Extraction of Angiotensin II J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1001 - 1006. [Abstract] [Full Text] [PDF] |
||||